[Inventory] Top 10 medical giants who are most willing to pay for research and development in 2016
Recently, FierceBiotech released a report entitled "The top 10 pharma R&D budgets in 2016", summarizing the top ten medical giants with the highest R&D budget in 2016. According to the company's 2016 annual report data, the TOP10 companies in the R&D budget have invested a total of 70.5 billion US dollars, of which Roche ranks first, with a research and development budget of 11.53 billion Swiss francs (11.42 billion US dollars), an increase of 20% compared with 2015. %. Johnson & Johnson and Novartis ranked second and third. AstraZeneca and BMS both accounted for more than 25% of the R&D budget as a percentage of revenue. However, their sales are ranked behind the pharmaceutical giant's sales list: AstraZeneca's sales last year was $23 billion, and BMS's sales last year were only $19.4 billion. In addition, it is worth mentioning that compared with 2015, BMS's R&D investment dropped by US$1 billion (16%) last year, the largest among the ten companies. AstraZeneca’s R&D spending last year also fell by 1.7%. R&D spending by other companies on the list has increased. Lilly's research and development expenses accounted for the third place in terms of revenue, which was 24.7%. The company's R&D investment last year was US$5.24 billion, up 9.3% from 2015. Johnson & Johnson's research and development expenses accounted for the lowest proportion of revenue, only 12.6%. Total R&D investment was $0.99 billion, of which $7 billion was for drug development. Johnson & Johnson's revenue last year was $71.9 billion, ranking first among ten companies. Earlier, according to the medical economic report, Pharma Intelligence recently released a global research report showing that in 2017, there were 14,872 pipeline drugs under research, an increase of 8.4% over 2016, showing a good growth trend. Between 2015 and 2016, the number of clinical phase III drugs under development increased by 18.1%. According to the report, the development of anti-tumor drugs is the fastest, among which breast cancer, non-small cell lung cancer and colorectal cancer are the most widely studied. In 2017, 669 anti-tumor drug candidates were added, with a growth rate of 16.0%. From the perspective of the types of drugs under study, biopharmaceuticals are in a period of rapid development, accounting for 37.8% in 2017, and there has been an upward trend in recent years. The following is part of the information on R&D investment in TOP companies: 1# Roche R&D budget (drugs and diagnostics): 11.53 billion Swiss francs ($11.42 billion) Changes compared to 2015: 20% increase 2016 total revenue: 50.57 billion Swiss francs R&D budget as percentage of revenue: 22.8% Specifically, Roche’s drug development spending has grown significantly, from 8.3 billion Swiss francs in 2015 to 10.1 billion Swiss francs last year. Diagnostic R&D expenditures have increased at a small rate, with an increase of 100 million Swiss francs in 2015 compared to 2015, totaling 1.3 billion Swiss francs. A key success of the company in research and development last year was that the FDA approved the launch of its immunotherapeutic Tecentriq. Tecentriq is also the first PD-L1 antibody approved by the FDA. Electric Balance,Weighing Balance,High Stability Balance,Electric Precision Balance Guangdong Widinlsa International Co.Ltd , https://www.gdwidinlsa.com
